LAVA Therapeutics NV (LVTX) Stock Price & Overview
NASDAQ:LVTX • NL0015000AG6
Current stock price
The current stock price of LVTX is 1.74 USD. Today LVTX is down by -3.87%. In the past month the price increased by 8.07%. In the past year, price increased by 8.75%.
LVTX Key Statistics
- Market Cap
- 45.779M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.86
- Dividend Yield
- N/A
LVTX Stock Performance
LVTX Stock Chart
LVTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX is one of the better performing stocks in the market, outperforming 75.73% of all stocks.
LVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LVTX. LVTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LVTX Earnings
LVTX Forecast & Estimates
7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.
For the next year, analysts expect an EPS growth of 7.87% and a revenue growth -100% for LVTX
LVTX Groups
Sector & Classification
LVTX Financial Highlights
Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 16.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.12% | ||
| ROE | -190.76% | ||
| Debt/Equity | 0 |
LVTX Ownership
LVTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LVTX
Company Profile
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Company Info
IPO: 2021-03-25
LAVA Therapeutics NV
Yalelaan 60
Utrecht UTRECHT NL
Employees: 34
Phone: 31630003035
LAVA Therapeutics NV / LVTX FAQ
What does LVTX do?
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Can you provide the latest stock price for LAVA Therapeutics NV?
The current stock price of LVTX is 1.74 USD. The price decreased by -3.87% in the last trading session.
What is the dividend status of LAVA Therapeutics NV?
LVTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of LVTX stock?
LVTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy LVTX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LVTX.
When does LAVA Therapeutics NV (LVTX) report earnings?
LAVA Therapeutics NV (LVTX) will report earnings on 2026-03-26, after the market close.